Equity Profile

GMED

Globus Medical, Inc.

Health CareHealth Care Equipment$10.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, specializing in innovative spinal surgery solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely watch.

Expected to be around $1.12.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and innovate within the health care sector.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GMED Q2-2026 Earnings Preview

Context

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, specializing in innovative spinal surgery solutions. With a market cap of $11 billion, it plays a crucial role in improving patient outcomes through advanced medical technology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, GMED reported an EPS of $1.12, surpassing estimates by 22%. However, the stock price fell by 4.65% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Focus on expanding product lines.
Commitment to improving operational efficiencies.
Plans to enhance customer service and support.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about GMED's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty to investor expectations.

Bull Case

If GMED continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially leading to a positive stock reaction.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if the EPS falls short of expectations, it could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.12.

EPS is a key indicator of the company's profitability and performance, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and innovate within the health care sector.

Market Reaction

Expected to move ±16.79%.

Understanding how the stock reacts post-earnings can provide insights into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive industry.

Will management provide any guidance on new product launches?

New product launches can significantly impact future sales and market share, making this information vital for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GMED's ability to innovate and capture market share, especially given recent trends in the health care equipment sector.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, reflecting uncertainty that could be resolved favorably.

Recent insider buying could signal confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will indicate whether GMED can maintain its growth trajectory amidst market challenges.

Bull Confirmed If

An EPS of $1.15 or higher with positive revenue growth would confirm the bullish outlook.

Bear Confirmed If

An EPS below $1.05 or negative revenue growth would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.79%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty and investor caution ahead of the earnings report.

Options are pricing ±16.8% while GMED has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.1%

Calls (2K)P/C Ratio: 4.19Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise around 0.08% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of about 1.33%, reflecting disappointment in performance and guidance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and growth initiatives.
5Responses to analyst questions regarding recent market trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, specializing in innovative spinal surgery solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely watch.

Expected to be around $1.12.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and innovate within the health care sector.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GMED Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, GMED reported an EPS of $1.12, surpassing estimates by 22%. However, the stock price fell by 4.65% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Focus on expanding product lines.
Commitment to improving operational efficiencies.
Plans to enhance customer service and support.

Expectations

Wall Street Expectations

Bull Case

If GMED continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially leading to a positive stock reaction.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if the EPS falls short of expectations, it could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.12.

EPS is a key indicator of the company's profitability and performance, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and innovate within the health care sector.

Market Reaction

Expected to move ±16.79%.

Understanding how the stock reacts post-earnings can provide insights into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive industry.

Will management provide any guidance on new product launches?

New product launches can significantly impact future sales and market share, making this information vital for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GMED's ability to innovate and capture market share, especially given recent trends in the health care equipment sector.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, reflecting uncertainty that could be resolved favorably.

Recent insider buying could signal confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will indicate whether GMED can maintain its growth trajectory amidst market challenges.

Bull Confirmed If

An EPS of $1.15 or higher with positive revenue growth would confirm the bullish outlook.

Bear Confirmed If

An EPS below $1.05 or negative revenue growth would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.79%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty and investor caution ahead of the earnings report.

Options are pricing ±16.8% while GMED has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.1%

Calls (2K)P/C Ratio: 4.19Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise around 0.08% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of about 1.33%, reflecting disappointment in performance and guidance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and growth initiatives.
5Responses to analyst questions regarding recent market trends.